DONATE
INDIANAPOLIS – Indiana will receive about $2.1 million from a multi-state settlement with GlaxoSmithKline.
Attorney General Greg Zoeller entered into the settlement with GlaxoSmithKline after resolving allegations the company misrepresented the uses of Paxil and Wellbutrin – both antidepressants – and Advair – an asthma drug.
The total settlement of $105 million will be divided among 45 attorneys general including Zoeller.
“Pharmaceutical companies are required to only promote a prescription drug for uses that have been approved by the FDA,” Zoeller said. “Off-label marketing can put patients unnecessarily at risk, which is why those decisions are best left to the treating physician and not the pharmaceutical companies.”
Through the settlement, GDK is required to continue its Patient First Program through March 2019, which reduces financial incentives for sales representatives. GDK is also required to change its marketing and promotional practices.
Emily Metheny is a reporter for TheStatehouseFile.com, a news website powered by Franklin College journalism students.
View More Articles
Support WFYI. We can't do it without you.